An assessment of neovascular AMD activity

Article

Looking at an activity socring system to define lesions associated with wet AMD by quantifying their activity to determine the need for treatment.

Key Points

Inactive

Activity scoring system

The proposed ASS is based on the well-known and widely used signs and findings of active CNV:

Apart from FA staining pattern, all of the other assessments are based on the changes in each parameter (same-baseline/increased/decreased) and given a number to define the activity. At the end of the assessment, the numbers are totalled and an activity score is obtained.

Activity scores (AS) can range between 0 and 14. We believe that a CNV lesion with AS of 6–7 or more requires treatment and <6 does not. We are currently compiling a paper to more accurately determine the cut off AS to separate those lesions that need treatment and those that do not.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.